GeneThera, Inc. (GTHR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | - USD | 100.0% |
| 2021 | -1 Million USD | -36.27% |
| 2020 | -740.61 Thousand USD | -0.2% |
| 2019 | -739.15 Thousand USD | 81.18% |
| 2018 | -3.92 Million USD | -548.3% |
| 2017 | -605.7 Thousand USD | 10.94% |
| 2016 | -680.06 Thousand USD | 24.51% |
| 2015 | -900.89 Thousand USD | -48.03% |
| 2014 | -608.6 Thousand USD | 44.67% |
| 2013 | -1.09 Million USD | 39.14% |
| 2012 | -1.8 Million USD | -62.19% |
| 2011 | -1.11 Million USD | -130.77% |
| 2010 | -482.9 Thousand USD | 62.82% |
| 2009 | -1.29 Million USD | 34.69% |
| 2008 | -1.98 Million USD | -136.21% |
| 2007 | -841.92 Thousand USD | 43.21% |
| 2006 | -1.48 Million USD | 55.76% |
| 2005 | -3.35 Million USD | 25.17% |
| 2004 | -4.47 Million USD | -75.26% |
| 2003 | -2.55 Million USD | -165.76% |
| 2002 | -961.48 Thousand USD | -230.8% |
| 2001 | -290.65 Thousand USD | -1500.61% |
| 2000 | -18.15 Thousand USD | 94.3% |
| 1999 | -318.85 Thousand USD | -195.05% |
| 1998 | -108.06 Thousand USD | -80.11% |
| 1997 | -60 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q1 | - USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 Q3 | -125.01 Thousand USD | 15.17% |
| 2022 Q1 | -132.18 Thousand USD | 52.4% |
| 2022 FY | - USD | 100.0% |
| 2022 Q4 | - USD | 100.0% |
| 2022 Q2 | -147.38 Thousand USD | -11.49% |
| 2021 Q3 | -242.22 Thousand USD | 14.93% |
| 2021 Q2 | -284.72 Thousand USD | -39.17% |
| 2021 Q4 | -277.72 Thousand USD | -14.66% |
| 2021 Q1 | -204.59 Thousand USD | -54.85% |
| 2021 FY | -1 Million USD | -36.27% |
| 2020 Q1 | -141.7 Thousand USD | 40.73% |
| 2020 Q2 | -194.06 Thousand USD | -36.95% |
| 2020 Q3 | -272.72 Thousand USD | -40.53% |
| 2020 Q4 | -132.12 Thousand USD | 51.55% |
| 2020 FY | -740.61 Thousand USD | -0.2% |
| 2019 Q3 | -204.32 Thousand USD | -48.61% |
| 2019 Q2 | -137.49 Thousand USD | 13.1% |
| 2019 Q1 | -158.22 Thousand USD | 94.93% |
| 2019 Q4 | -239.1 Thousand USD | -17.02% |
| 2019 FY | -739.15 Thousand USD | 81.18% |
| 2018 Q3 | -313.55 Thousand USD | -0.77% |
| 2018 Q1 | -202.17 Thousand USD | -48.33% |
| 2018 FY | -3.92 Million USD | -548.3% |
| 2018 Q4 | -3.12 Million USD | -895.1% |
| 2018 Q2 | -311.16 Thousand USD | -53.91% |
| 2017 Q3 | -109.98 Thousand USD | 4.24% |
| 2017 FY | -605.7 Thousand USD | 10.94% |
| 2017 Q1 | -244.56 Thousand USD | -133.8% |
| 2017 Q2 | -114.85 Thousand USD | 53.04% |
| 2017 Q4 | -136.29 Thousand USD | -23.92% |
| 2016 Q1 | -260.75 Thousand USD | -29.65% |
| 2016 FY | -680.06 Thousand USD | 24.51% |
| 2016 Q4 | -104.6 Thousand USD | 15.2% |
| 2016 Q3 | -123.35 Thousand USD | 35.54% |
| 2016 Q2 | -191.35 Thousand USD | 26.62% |
| 2015 FY | -900.89 Thousand USD | -48.03% |
| 2015 Q1 | -348.88 Thousand USD | -217.83% |
| 2015 Q2 | -147.53 Thousand USD | 57.71% |
| 2015 Q3 | -203.36 Thousand USD | -37.84% |
| 2015 Q4 | -201.12 Thousand USD | 1.1% |
| 2014 Q3 | -118.76 Thousand USD | 44.53% |
| 2014 Q1 | -165.97 Thousand USD | 11.61% |
| 2014 FY | -608.6 Thousand USD | 44.67% |
| 2014 Q4 | -109.77 Thousand USD | 7.57% |
| 2014 Q2 | -214.09 Thousand USD | -28.99% |
| 2013 Q2 | -282.05 Thousand USD | -1.23% |
| 2013 FY | -1.09 Million USD | 39.14% |
| 2013 Q4 | -187.77 Thousand USD | 46.97% |
| 2013 Q3 | -354.07 Thousand USD | -25.54% |
| 2013 Q1 | -278.61 Thousand USD | 60.97% |
| 2012 Q1 | -515.11 Thousand USD | -170.12% |
| 2012 Q2 | -337.57 Thousand USD | 34.47% |
| 2012 FY | -1.8 Million USD | -62.19% |
| 2012 Q4 | -713.77 Thousand USD | -196.28% |
| 2012 Q3 | -240.91 Thousand USD | 28.63% |
| 2011 FY | -1.11 Million USD | -130.77% |
| 2011 Q1 | -142.47 Thousand USD | 19.12% |
| 2011 Q4 | 734.67 Thousand USD | 148.13% |
| 2011 Q2 | -186.66 Thousand USD | -31.01% |
| 2011 Q3 | -1.52 Million USD | -717.76% |
| 2010 FY | -482.9 Thousand USD | 62.82% |
| 2010 Q1 | -108.52 Thousand USD | -74.99% |
| 2010 Q2 | -89.79 Thousand USD | 17.26% |
| 2010 Q4 | -176.16 Thousand USD | -62.47% |
| 2010 Q3 | -108.42 Thousand USD | -20.75% |
| 2009 Q1 | -313.91 Thousand USD | -120.94% |
| 2009 Q3 | -626.87 Thousand USD | -111.83% |
| 2009 Q2 | -295.93 Thousand USD | 5.73% |
| 2009 Q4 | -62.01 Thousand USD | 90.11% |
| 2009 FY | -1.29 Million USD | 34.69% |
| 2008 Q4 | 1.49 Million USD | 148.06% |
| 2008 Q2 | -158.49 Thousand USD | 16.53% |
| 2008 Q1 | -189.86 Thousand USD | -35.75% |
| 2008 Q3 | -3.11 Million USD | -1867.87% |
| 2008 FY | -1.98 Million USD | -136.21% |
| 2007 Q1 | -219.75 Thousand USD | 59.8% |
| 2007 FY | -841.92 Thousand USD | 43.21% |
| 2007 Q4 | -139.86 Thousand USD | 6.04% |
| 2007 Q3 | -148.86 Thousand USD | 57.44% |
| 2007 Q2 | -349.8 Thousand USD | -59.18% |
| 2006 Q3 | -503.29 Thousand USD | -34.22% |
| 2006 Q4 | -546.61 Thousand USD | -8.61% |
| 2006 FY | -1.48 Million USD | 55.76% |
| 2006 Q1 | -150.29 Thousand USD | 52.55% |
| 2006 Q2 | -374.96 Thousand USD | -149.48% |
| 2005 FY | -3.35 Million USD | 25.17% |
| 2005 Q1 | -2.18 Million USD | -119.01% |
| 2005 Q2 | -366.01 Thousand USD | 83.26% |
| 2005 Q3 | -533.52 Thousand USD | -45.77% |
| 2005 Q4 | -316.73 Thousand USD | 40.63% |
| 2004 Q4 | 11.5 Million USD | 4315.16% |
| 2004 Q3 | -272.92 Thousand USD | 98.19% |
| 2004 Q2 | -15.09 Million USD | -2363.95% |
| 2004 Q1 | -612.72 Thousand USD | 70.91% |
| 2004 FY | -4.47 Million USD | -75.26% |
| 2003 Q1 | -69.47 Thousand USD | 58.77% |
| 2003 FY | -2.55 Million USD | -165.76% |
| 2003 Q4 | -2.1 Million USD | -964.92% |
| 2003 Q3 | -197.8 Thousand USD | -8.99% |
| 2003 Q2 | -181.48 Thousand USD | -161.23% |
| 2002 Q4 | -168.52 Thousand USD | 15.27% |
| 2002 FY | -961.48 Thousand USD | -230.8% |
| 2002 Q1 | -271.16 Thousand USD | 6.71% |
| 2002 Q2 | -322.91 Thousand USD | -19.09% |
| 2002 Q3 | -198.88 Thousand USD | 38.41% |
| 2001 FY | -290.65 Thousand USD | -1500.61% |
| 2001 Q4 | -290.65 Thousand USD | -346.32% |
| 2001 Q3 | -65.12 Thousand USD | 66.2% |
| 2001 Q2 | -192.68 Thousand USD | -439.76% |
| 2001 Q1 | -35.69 Thousand USD | -125.9% |
| 2000 Q1 | -59.87 Thousand USD | 76.97% |
| 2000 Q2 | -77.91 Thousand USD | -30.13% |
| 2000 Q3 | -22.21 Thousand USD | 71.49% |
| 2000 Q4 | 137.85 Thousand USD | 720.67% |
| 2000 FY | -18.15 Thousand USD | 94.3% |
| 1999 Q3 | 20 Thousand USD | 300.0% |
| 1999 Q1 | -60 Thousand USD | 0.0% |
| 1999 FY | -318.85 Thousand USD | -195.05% |
| 1999 Q4 | -260 Thousand USD | -1400.0% |
| 1999 Q2 | -10 Thousand USD | 83.33% |
| 1998 FY | -108.06 Thousand USD | -80.11% |
| 1998 Q4 | - USD | 0.0% |
| 1997 FY | -60 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 100.0% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 100.0% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 100.0% |
| Nascent Biotech, Inc. | -2.22 Million USD | 100.0% |
| Rebus Holdings, Inc. | -664 Thousand USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.0% |
| Qrons Inc. | -643.67 Thousand USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 100.0% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 100.0% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | -13.67 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 100.0% |
| SQZ Biotechnologies Company | -75.82 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 100.0% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 100.0% |
| Mesoblast Limited | -84.14 Million USD | 100.0% |
| Marizyme, Inc. | -34.08 Million USD | 100.0% |
| Genus plc | 6.4 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 100.0% |
| Pharming Group N.V. | -4.87 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 100.0% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 100.0% |
| ContraFect Corporation | -56.88 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 100.0% |
| IMV Inc. | -38.67 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 100.0% |
| MultiCell Technologies, Inc. | -722.81 USD | 100.0% |
| ONE Bio Corp. | 13.68 Million USD | 100.0% |
| Accustem Sciences Inc. | -3.74 Million USD | 100.0% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| EV Biologics, Inc. | -483.06 Thousand USD | 100.0% |
| Q BioMed Inc. | -3.44 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 100.0% |
| Biomind Labs Inc. | -1 Million USD | 100.0% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 100.0% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 100.0% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 100.0% |
| GB Sciences, Inc. | -1.42 Million USD | 100.0% |
| Alpha Cognition Inc. | -9.7 Million USD | 100.0% |
| HST Global, Inc. | -140.9 Thousand USD | 100.0% |
| CSL Limited | 3.7 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 100.0% |
| Halberd Corporation | -75.05 Thousand USD | 100.0% |
| Enzolytics Inc. | -2.14 Million USD | 100.0% |
| Agentix Corp. | -1.37 Million USD | 100.0% |
| Resverlogix Corp. | -12.74 Million USD | 100.0% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | -425.04 Million USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 100.0% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 100.0% |
| AVAX Technologies, Inc. | 6.69 Million USD | 100.0% |
| Zenith Capital Corp. | -8.94 Million USD | 100.0% |
| Genscript Biotech Corporation | -415.79 Million USD | 100.0% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 100.0% |
| Kadimastem Ltd | -3.04 Million USD | 100.0% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 100.0% |
| BioStem Technologies, Inc. | -7.77 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 100.0% |
| LadRx Corporation | -3.82 Million USD | 100.0% |
| Cell Source, Inc. | -4.32 Million USD | 100.0% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 100.0% |
| NovAccess Global Inc. | -2.46 Million USD | 100.0% |
| Affymax, Inc. | -15.04 Million USD | 100.0% |
| Itoco Inc. | -919.14 Thousand USD | 100.0% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 100.0% |
| Mobile Lads Corp. | -554.55 Thousand USD | 100.0% |
| CytoDyn Inc. | -18.05 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 100.0% |
| SYBLEU INC | -149.18 Thousand USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 100.0% |
| International Stem Cell Corporation | -663 Thousand USD | 100.0% |
| Bioxytran, Inc. | -3.82 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | -36.26 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 100.0% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | -735.83 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 100.0% |
| Neutra Corp. | -229.48 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 100.0% |
| PureTech Health plc | -146.19 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 100.0% |
| IXICO plc | -1.43 Million USD | 100.0% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 100.0% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 100.0% |
| CSL Limited | 3.81 Billion USD | 100.0% |
| Cellectis S.A. | -108.85 Million USD | 100.0% |